CAR-T-Cell-Therapy-Pipeline-Insights

DelveInsight’s CAR T-Cell Therapy pipeline report gives extensive insights into the CAR T-Cell Therapy pipeline landscape, including 250+ companies and 250+ pipeline therapies. It includes clinical and nonclinical stage medicines in the pipeline medication profiles. It also examines medicines by product type, stage, administration route, and molecule type.

Some of the Crucial Highlights from the CAR T-Cell Therapy Pipeline Report

  • There are currently 250+ CAR T-Cell Therapy pipeline therapies in various stages of development.
  • Bluebird Bio, Cartesian Therapeutics, Autolus Limited, Novartis, BioAtla, JW Therapeutics, and others are among the leading companies involved in the CAR T-Cell Therapy pipeline landscape.
  • The National Medical Products Administration (“NMPA”) approved JWCAR029 (JW Therapeutics) NDA for relma-cel as a third-line treatment for DLBCL for evaluation in June 2020, and was granted priority review status in September 2020.
  • Pipeline therapies such as CTL119 and BA 3011 are in the Phase II of CAR T-Cell Therapy clinical trials. While pipeline therapies which are in Phase I/II of CAR T-Cell Therapy clinical trials include Descartes-08, AUTO4, along with others.
  • Some pipeline therapies for CAR T-Cell Therapy such as bb21217, and others are in the early phase of development, i.e. Phase I of CAR T-Cell Therapy clinical trials.

To learn more, request sample @ CAR T-Cell Therapy Clinical Trials

CAR T-Cell Therapy: Overview

CAR T-cells are fusion proteins made up of one or more T-cell receptor intracellular signalling domains with a single-chain fragment varying from a monoclonal antibody. 

CAR T-Cell Therapy involves genetically modifying a patient’s autologous T-cells to express a CAR that recognises a tumour antigen, followed by ex vivo cell multiplication and re-infusion. CAR T-Cell Therapies are being used to treat malignancies of all kinds.

CAR T-Cell Therapy Pipeline Analysis: Drug Profiles 

JWCAR029: JW Therapeutics

Product Description

JWCAR029 (Relmacabtagene autoleucel) is a CAR-T cell product that targets CD19 and is being developed as a third-line treatment for relapsed or refractory (r/r) B-cell lymphoma.

Phase II

NCT04089215: In June 2019, a phase II, open-label, single-arm, multicenter research in China was launched to assess the efficacy and safety of JWCAR029 in adult R/R Non-Hodgkin’s Lymphoma patients. This is a multicenter, phase II, open-label, single-arm research in adult individuals with R/R Non-Hodgkin’s Lymphoma in China to assess the safety, effectiveness, pharmacokinetics (PK), and pharmacodynamics (PD) of JWCAR029.

Get in touch to know more about the CART T-Cell Therapy FDA Approval

CAR T-Cell Therapy Pipeline Therapies and Key Companies 

  • bb21217: Bluebird Bio
  • Descartes-08: Cartesian Therapeutics
  • AUTO4: Autolus Limited
  • CTL119: Novartis
  • BA 3011: BioAtla
  • WCAR029: JW Therapeutics

CAR T-Cell Therapy Therapeutics Assessment

  • By Product Type
    • Monotherapy
    • Combination Therapy
  • By Stage
    • Discovery
    • Pre-Clinical
    • Phase I
    • Phase II
    • Phase III
    • Pre-registration
  • By Route of Administration
    • Inhalation
    • Intravenous
    • Oral
    • Subcutaneous
  • By Molecule Type
    • Small Molecule
    • Stem Cell Therapy
    • Gene Therapy
  • Targets
    • Immune System
    • Multiple Kinase
    • Protease
  • By Mechanism of Action
    • Protease Inhibitors
    • Immunomodulatory
    • Multiple Kinase Inhibitors

Scope of the Report

Coverage: Global

CAR T-Cell Therapy Key Players: Bluebird Bio, Cartesian Therapeutics, Autolus Limited, Novartis, BioAtla, JW Therapeutics, among others

CAR T-Cell Therapy Pipeline Therapies: bb21217, Descartes-08, AUTO4, CTL119, BA 3011, WCAR029,  and others

Table of Contents

1. Key Insights
2. Report Introduction
3. CAR T-Cell Therapy: Snapshot
4. CAR T-Cell Therapy: Overview
5. CAR T-Cell Therapy Pipeline Scenario
6. CAR T-Cell Therapy Pipeline Therapeutics
7. CAR T-Cell Therapy Late Stage Products (Registered)
8. CAR T-Cell Therapy Late Stage Products (Pre-registration)
9. CAR T-Cell Therapy Mid Stage Products (Phase II)
10. CAR T-Cell Therapy Early Stage Products (Phase I/II)
11. CAR T-Cell Therapy Early Stage Products (Phase I)
12. CAR T-Cell Therapy IND-stage Products
13. CAR T-Cell Therapy Preclinical stage Products
14. CAR T-Cell Therapy Discovery stage Products
15. CAR T-Cell Therapy Therapeutic Assessment
16. CAR T-Cell Therapy Inactive Products
17. CAR T-Cell Therapy- Unmet Needs
18. CAR T-Cell Therapy- Market Drivers and Barriers
19. Appendix
20. About DelveInsight

Know more what’s covered in the CAR T-Cell Therapy Assessment Report

Key Questions Answered in the CAR T-Cell Therapy Pipeline Report

  • What are the possibilities for CAR T-Cell Therapy treatment?
  • How many pharmaceutical companies are developing CAR T-Cell Therapy treatments?
  • Which of these companies’ medicines are the most popular?
  • What is the total number of CAR T-Cell Therapy therapies produced by each company?
  • How many CAR T-Cell Therapy pipeline medications are in the early, mid, or late stages of development?
  • How many of the therapies in development can be used on their own or in combination with other treatments?
  • What are the most significant industry-industry and industry-academy collaborations, mergers and acquisitions, and licencing practises affecting CAR T-Cell Therapy?

Related Reports

CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Pipeline Insights

Get a comprehensive analysis of CAR T-Cell Therapy for Acute Lymphoblastic Leukemia pipeline therapies and key companies including Autolus, PersonGen Biotherapeutics, Pepromene Bio, Inc., Actinium Pharmaceuticals, among others.

CAR T-Cell Therapy for Multiple Myeloma Pipeline Insights

Get a comprehensive analysis of CAR T-Cell Therapy for Multiple Myeloma pipeline therapies and key companies including Novartis, Janssen Biotech, Yake Biotech, Celgene Corporation, among others.

CAR T Related Neurotoxicity Pipeline Insights

“CART related Neurotoxicity (NT) Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the CART related Neurotoxicity (NT) market.

CAR T-Cell Therapy for Non Hodgkin’s Lymphoma Pipeline Insights

Get comprehensive analysis of CAR T-Cell Therapy for Non Hodgkin’s Lymphoma pipeline therapies and key companies including Juno Therapeutics, Caribou Biosciences, Allogene Therapeutics, among others.

Neo Antigen T Cell Therapy Pipeline Insights

“Neo Antigen T-Cell Therapy Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Neo Antigen T-Cell Therapy market.

T Cell Therapy Pipeline Insights

“T Cell Therapy Pipeline Insight, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the T Cell Therapy market.

Lymphatic Malformations Pipeline Insights

Get comprehensive analysis of Lymphatic Malformations pipeline therapies and key companies including Vanthera, Cerecor, Inc., Protara therapeutics, among others.

Necrobiosis Lipoidica Pipeline Insights

Get comprehensive analysis of Necrobiosis Lipoidica pipeline therapies and key companies including Novartis, Processa Pharmaceuticals, among others. 

Recurrent Malignant Glioma Pipeline Insights

Recurrent Malignant Glioma Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Recurrent Malignant Glioma market.

Gliosarcoma Pipeline Insights

Gliosarcoma Pipeline Insights, 2021” report by DelveInsight outlays comprehensive insights of present clinical development scenarios and growth prospects across the Gliosarcoma market.

Related Posts

CAR T-Cell Therapy Market for Non Hodgkin Lymphoma

Chimeric Antigen Receptor Therapies in Blood Cancers

CAR T-Cell Therapy Market in Acute Lymphoblastic Leukemia

Get in touch with our Business executive @ CAR T-Cell Therapy Pipeline Insights to know more

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing end to end comprehensive solutions to improve their performance. 

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us 

Sandeep Joshi 

[email protected] 

+1(919)321-6187 

www.delveinsight.com

Connect With Us at:

LinkedIn | Facebook | Twitter

Tags: CAR T Cell Therapy, CAR T-Cell Therapy Companies, CAR T-Cell Therapy Pipeline, CAR T-Cell Therapy FDA Approval, CAR T-Cell Therapy Clinical Trials, CAR T-Cell Therapy Multiple Myeloma

Contact Information:

Sandeep Joshi 

[email protected] 

+1(919)321-6187